Loading…

Enhancing immunomodulatory properties of Javanese turmeric (Curcuma xanthorrhiza) kombucha against diethylnitrosamine in male Balb/c mice

Kombucha is a fermented tea beverage, made by the addition of symbiotic culture of bacteria and yeasts (SCOBY). This study utilized Javanese turmeric in a concentration of 0.4 % (w/v) as a kombucha fermentation medium and evaluated its immunomodulatory activity, compared to non-fermented Javanese tu...

Full description

Saved in:
Bibliographic Details
Published in:Process biochemistry (1991) 2023-10, Vol.133, p.303-308
Main Authors: Zubaidah, Elok, Charista Dea, Eirene, Rahayu, Aldilla Putri, Fibrianto, Kiki, Saparianti, Ella, Sujuti, Hidayat, Godelive, Laura, Srianta, Ignatius, Tewfik, Ihab
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Kombucha is a fermented tea beverage, made by the addition of symbiotic culture of bacteria and yeasts (SCOBY). This study utilized Javanese turmeric in a concentration of 0.4 % (w/v) as a kombucha fermentation medium and evaluated its immunomodulatory activity, compared to non-fermented Javanese turmeric beverage. Forty-two healthy male BalB/C mice (20–30 g, 2–3 weeks old) were divided randomly into five groups with seven mice each. The groups were fed: Normal diet; normal diet + Javanese turmeric kombucha; normal diet + diethylnitrosamine (DEN); DEN + non-fermented Javanese turmeric and DEN + Javanese turmeric kombucha. Kombuchas and non-fermented Javanese turmeric were given at dose of 0.3 mL/20 g BW/day. The mice were injected with 100 mg/kg DEN intraperitoneally. The spleen was collected and analyzed for CD4+, tumor necrosis factor α (TNF-α+), interleukin-6 (IL-6+), CD8+, CD11b+, and IL-10+. The statistical analyses included ANOVA and the Fischer’s exact test. The percentage of CD8+, CD11b+, and CD8+ IL-10+ increased significantly (p 
ISSN:1359-5113
1873-3298
DOI:10.1016/j.procbio.2023.09.012